---
title: "TG Therapeutics Q2 2026 earnings preview"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294529590.md"
description: "TG Therapeutics (TGTX) will report Q2 2026 earnings on August 3rd. Consensus estimates project EPS of $0.44 and revenue of $229.79M, a 62.8% year-over-year increase. Analyst sentiment is positive, with EPS estimates seeing four upward revisions in the last three months, while revenue estimates have experienced seven upward revisions and no downward adjustments."
datetime: "2026-07-31T14:50:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294529590.md)
  - [en](https://longbridge.com/en/news/294529590.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294529590.md)
generator: "portal-rs"
---

# TG Therapeutics Q2 2026 earnings preview

TG Therapeutics (TGTX) is scheduled to announce Q2 earnings results on Monday, August 3rd, before market open. The consensus EPS Estimate is $0.44 and the consensus Revenue Estimate is $229.79M (+62.8% Y/Y). Over the last 3 months, EPS estimates have seen 4 upward revisions and 1 downward. Revenue estimates have seen 7 upward revisions and 0 downwa...

### Related Stocks

- [TGTX.US](https://longbridge.com/en/quote/TGTX.US.md)

## Related News & Research

- [TGTX Stock Alert: What to Know as Takeover Rumors Swirl Around TG Therapeutics](https://longbridge.com/en/news/296647082.md)
- [TGTX: Record BRIUMVI growth and raised guidance highlight a strong quarter and expanding franchise](https://longbridge.com/en/news/294709467.md)
- [Tredegar (NYSE:TG) Insider Arijit Dasgupta Acquires 2,093 Shares of Stock](https://longbridge.com/en/news/296278499.md)
- [Tredegar (NYSE:TG) Major Shareholder William Gottwald Sells 7,718 Shares](https://longbridge.com/en/news/296383737.md)
- [Dexco executives sign off on interim financial statements for quarter ended June 30, 2026](https://longbridge.com/en/news/296656862.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**